Shares of Moderna, Inc. (NASDAQ: 
MRNA) saw a noteworthy uptick of 15% in Wednesday's trading session extending gains to Thursday's premarket session surging 4.34%
Shares ofMRNA has already broke the ceiling of a falling wedge. eyeing a 100% surge should market conditions remain positive as the company awaits earnings report February, 2026.
In recent news, Moderna (MRNA.O), and Merck (MRK.N), said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of the most deadly skin cancer five years after the treatment started.
In a mid‑stage study of high‑risk melanoma patients who had undergone surgery, the vaccine combined with Merck's Keytruda reduced the risk of recurrence or death by 49% after five years, consistent with the three-year follow-up data in 2023.
The data points to an early success for Moderna as it seeks to turn its mRNA platform into a broader, durable franchise and plug the revenue gap left by waning COVID demand.
"If Moderna can recreate this 49% risk reduction in the much larger phase 3 trial, that bodes well for not only commercialization in melanoma but also prospects for the combination in other indications, like kidney, bladder, and lung cancers,"
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccine.
MRNA) saw a noteworthy uptick of 15% in Wednesday's trading session extending gains to Thursday's premarket session surging 4.34%Shares of
MRNA has already broke the ceiling of a falling wedge. eyeing a 100% surge should market conditions remain positive as the company awaits earnings report February, 2026. In recent news, Moderna (MRNA.O), and Merck (MRK.N), said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of the most deadly skin cancer five years after the treatment started.
In a mid‑stage study of high‑risk melanoma patients who had undergone surgery, the vaccine combined with Merck's Keytruda reduced the risk of recurrence or death by 49% after five years, consistent with the three-year follow-up data in 2023.
The data points to an early success for Moderna as it seeks to turn its mRNA platform into a broader, durable franchise and plug the revenue gap left by waning COVID demand.
"If Moderna can recreate this 49% risk reduction in the much larger phase 3 trial, that bodes well for not only commercialization in melanoma but also prospects for the combination in other indications, like kidney, bladder, and lung cancers,"
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccine.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.